Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.

Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.

Item
http://www.wikidata.org/entity/Q42553519
Computerized advice on drug dosage to improve prescribing practiceComputerized advice on drug dosage to improve prescribing practiceBenefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysisTwenty years of health care economic analysis in Spain: are we doing well?Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity.Optimization of time to initial vancomycin target trough improves clinical outcomesThe 6R's of drug induced nephrotoxicityInfluence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of AmericaTherapeutic drug monitoring: is it cost-effective?Is therapeutic drug monitoring of teicoplanin useful?Vancomycin nephrotoxicity: a review.Pharmacokinetics and dose requirements of vancomycin in neonates.A New Method for Individualized Digoxin Dosing in Elderly Patients.High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures.
P2860

Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.

Item
http://www.wikidata.org/entity/Q42553519
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Cost-effectiveness analysis of ...... with hematologic malignancies.
@en
Cost-effectiveness analysis of ...... with hematologic malignancies.
@nl
type
label
Cost-effectiveness analysis of ...... with hematologic malignancies.
@en
Cost-effectiveness analysis of ...... with hematologic malignancies.
@nl
prefLabel
Cost-effectiveness analysis of ...... with hematologic malignancies.
@en
Cost-effectiveness analysis of ...... with hematologic malignancies.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Cost-effectiveness analysis of ...... with hematologic malignancies.
@en
P2093
P304
P31
P356
10.1016/S0009-9236(96)90060-0
P407
P433
P478
P577
P698